{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:38:30Z","timestamp":1764239910117},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.jbspin.2014.02.015","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T01:04:13Z","timestamp":1435021453000},"page":"225-229","source":"Crossref","is-referenced-by-count":7,"title":["Rational pharmacotherapy (RPT) in goutology: Define the serum uric acid target & treat-to-target patient cohort and review on urate lowering therapy (ULT) applying synthetic drugs"],"prefix":"10.1016","volume":"82","author":[{"given":"Tim L.","family":"Jansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2014.02.015_bib0005","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2014.02.015_bib0010","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2014.02.015_bib0015","first-page":"150","article-title":"Ulodesine long-term safety when added to allopurinol in the chronic management of gout: a phase 2 24-week blinded safety extension and vaccine challenge study","volume":"64","author":"Hollister","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2014.02.015_bib0020","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/ket487","article-title":"Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia","author":"Fleischmann","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2014.02.015_bib0025","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10067-006-0528-3","article-title":"Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients","volume":"26","author":"Reinders","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2014.02.015_bib0030","first-page":"651","article-title":"Benzbromarone withdrawn from the European market: another case of \u201cabsence of evidence is evidence of absence\u201d?","volume":"22","author":"Jansen","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2014.02.015_bib0035","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","article-title":"A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?","volume":"31","author":"Lee","year":"2008","journal-title":"Drug Safety"},{"key":"10.1016\/j.jbspin.2014.02.015_bib0040","doi-asserted-by":"crossref","first-page":"e12184","DOI":"10.1371\/journal.pone.0012184","article-title":"Routine laboratory results and thirty day and one-year mortality risk following hospitalization with acute decompensate heart failure","volume":"5","author":"Novack","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jbspin.2014.02.015_bib0045","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/heapol\/14.2.89","article-title":"Intervention research in rational use of drugs: a review","volume":"14","author":"le Grand","year":"1999","journal-title":"Health Policy Plan"},{"key":"10.1016\/j.jbspin.2014.02.015_bib0050","unstructured":"Kutyabami P. \u201cRational drug use\u201d as a public health concept (in developing world). Available from: http:\/\/www.cwru.edu\/med\/epidbio\/mphp439\/Rational%20Drug%20Use.htm."},{"key":"10.1016\/j.jbspin.2014.02.015_bib0055","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S0140-6736(95)92472-8","article-title":"Impact of a short course in pharmacotherapy for undergraduate medical students: an international randomized controlled study","volume":"346","author":"De Vries","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2014.02.015_bib0060","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1002\/art.27667","article-title":"Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1beta production via the ASC\/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis","volume":"62","author":"Joosten","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2014.02.015_bib0065","first-page":"892","article-title":"A randomised-controlled trial with dose-escalation on the efficacy and tolerability of allopurinol 300\u2013600mg\/day versus benzbromazrone 100\u2013200mg\/day in gout patients","volume":"68","author":"Reinders","year":"2009","journal-title":"ARD"},{"key":"10.1016\/j.jbspin.2014.02.015_bib0070","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/ar3191","article-title":"A proposal for identifying the low renal uric acid clearance phenotype","volume":"12","author":"Indraratna","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2014.02.015_bib0075","doi-asserted-by":"crossref","first-page":"44","DOI":"10.7326\/0003-4819-91-1-44","article-title":"Uric acid excretion: a quantitative assessment from spot, midmorning serum and urine samples","volume":"91","author":"Simkin","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2014.02.015_bib0080","doi-asserted-by":"crossref","first-page":"R189","DOI":"10.1186\/ar4020","article-title":"Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients","volume":"14","author":"Kannangara","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2014.02.015_bib0085","article-title":"Enhanced IL-1beta and IL-6 production in gout patients upon stimulation with MSU crystals and synergizing agents when compared with healthy volunteers","author":"Crisan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2014.02.015_bib0090","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/art.30649","article-title":"A two-stage approach to the treatment of hyperuricemia in gout: the \u201cdirty dish\u201d hypothesis","volume":"63","author":"Perez-Ruiz","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2014.02.015_bib0095","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jbspin.2015.01.002","article-title":"Hyperuricemia Starts at 360 Micromoles (6mg\/dL)","volume":"82","author":"Bardin","year":"2015","journal-title":"Joint Bone Spine"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X14001079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X14001079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T11:23:16Z","timestamp":1537528996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X14001079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S1297319X14001079"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2014.02.015","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}